A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus

Inclusion Criteria:

- Body Mass Index (BMI) greater than or equal to (>=) 35 to less than or equal to (<=)
50 kilogram per meter square (kg/m^2) at screening

- Stable weight (that is, change of <= 5 percent [%] within 12 weeks before screening
based on medical or participant reported history)

- Hemoglobin A1c of >= 6.5% and <= 9.5% at screening and meets one of the inclusion
criteria as: (a) on diet and exercise alone >= 12 weeks prior to screening; (b) on
stable dose of single oral antihyperglycemic agent (AHA) or dual-combination oral AHAs
for >= 12 weeks prior to screening

- Women must be either: (a) Postmenopausal, or (b) Permanently sterilized or otherwise
be incapable of pregnancy, or (c) Heterosexually active and practicing a highly
effective method of birth control, or (d) Not heterosexually active

- Willing and able to adhere to specific the prohibitions and restrictions

Exclusion Criteria:

- History of obesity with a known secondary cause (example, Cushing's disease/syndrome)

- History of Type 1 diabetes mellitus, diabetic ketoacidosis, pancreas or beta-cell
transplantation, or diabetes secondary to pancreatitis or pancreatectomy

- Fasting C-peptide less than (<) 0.7 nanogram per milliliter (ng/mL) at screening

- Fasting fingerstick glucose of >= 270 milligram per deciliter (mg/dL) (>=15 millimoles
per liter [mmol/L]) on Day 1

- Ongoing, inadequately controlled thyroid disorder as assessed by the investigator's
review of the participant's medical history. Participants taking thyroid hormone
replacement therapy must be on stable doses for at least 6 weeks before the screening
visit